TY - JOUR
T1 - Opioid antagonists
T2 - A review of their role in palliative care, focusing on use in opioid-related constipation
AU - Choi, Youn Seon
AU - Billings, J. Andrew
N1 - Funding Information:
Dr. Billings is a Faculty Scholar of the Project on Death in America. This work was supported, in part, by a grant from the Robert Wood Johnson Foundation and by the John D. Stoeckle Center at the Massachusetts General Hospital.
PY - 2002
Y1 - 2002
N2 - Opioid antagonists have well-established indications in the reversal of life-threatening opioid toxicity, but also hold considerable promise for other applications in palliative care practice, particularly management of opioid-related constipation. We briefly review current understanding of opioid receptors, focusing on their complex role in gastrointestinal physiology. We summarize the pharmacology, conventional indications, and clinical usage of three major groups of opioid antagonists, including a promising new peripherally acting agent, methylnaltrexone, which is not commercially available. We suggest an approach to administering opioid antagonists for reduction of life-threatening opioid toxicity in patients with pain. The literature on opioid-induced constipation and its treatment with opioid-antagonists is reviewed in detail. Finally, other potential uses of opioid antagonists in palliative care are described, especially strategies for reducing such opioid side effects as nausea and pruritus and for improving analgesia or reducing tolerance by concomitantly administrating both an opioid agonist and low dosages of an antagonist.
AB - Opioid antagonists have well-established indications in the reversal of life-threatening opioid toxicity, but also hold considerable promise for other applications in palliative care practice, particularly management of opioid-related constipation. We briefly review current understanding of opioid receptors, focusing on their complex role in gastrointestinal physiology. We summarize the pharmacology, conventional indications, and clinical usage of three major groups of opioid antagonists, including a promising new peripherally acting agent, methylnaltrexone, which is not commercially available. We suggest an approach to administering opioid antagonists for reduction of life-threatening opioid toxicity in patients with pain. The literature on opioid-induced constipation and its treatment with opioid-antagonists is reviewed in detail. Finally, other potential uses of opioid antagonists in palliative care are described, especially strategies for reducing such opioid side effects as nausea and pruritus and for improving analgesia or reducing tolerance by concomitantly administrating both an opioid agonist and low dosages of an antagonist.
KW - Constipation
KW - Gastrointestinal motility
KW - Nalmephene
KW - Naloxone
KW - Naltrexone
KW - Narcotic antagonists
KW - Nausea/vomiting
KW - Opioid-related disorders
KW - Pruritus
KW - Respiratory depression
KW - Substace-related disorders
UR - http://www.scopus.com/inward/record.url?scp=0036056767&partnerID=8YFLogxK
U2 - 10.1016/S0885-3924(02)00424-4
DO - 10.1016/S0885-3924(02)00424-4
M3 - Review article
C2 - 12183097
AN - SCOPUS:0036056767
SN - 0885-3924
VL - 24
SP - 71
EP - 90
JO - Journal of Pain and Symptom Management
JF - Journal of Pain and Symptom Management
IS - 1
ER -